Researchers have identified key components of cell dysfunction that cause cancer

Scientists have locked a key step in the sequence of chemical reactions that control cell division, proliferation, and death, and failure of these chemical reactions can lead to tumor growth

The research will be published in the journal Communication Biology on November 1, 2021

In biology, the term "signaling pathway" describes a cascade of chemical reactions through which specific molecules act to control cell functions

Many cancers are the product of uncontrolled cell division.

However, the exact mechanism of YAP/TAZ activation is unclear

Therefore, EGFR is a common target for anti-cancer treatment, whether it is using kinase inhibitor drugs or blocking antibodies

"In some cell systems, EGFR cannot reduce the phosphorylation of YAP, but in other cell systems, it inhibits the Hippo pathway from activating YAP.

Therefore, the researchers carried out a series of studies on the mechanism of the Hippo pathway, including comparing the activation (expression) of the EGFR gene in a series of HNSCC cancer cells with the activation of YAP; in the head and neck squamous cell carcinoma cells, the cells with the most EGFR expression ; Analysis of all cancer types; and Gene Set Enrichment Analysis (GSEA)-a technique to identify gene groups that are overrepresented in a large gene set and may be related to certain diseases

They found that the activation of EGFR can promote the tyrosine phosphorylation of MOB1, one of the core components of the Hippo pathway

"Emerging evidence shows that YAP causes tumor growth, poor prognosis, and acquired drug resistance, the EGFR-targeted drug HNSCC LUAC, although the mechanism of barking reactivation is still unclear," J.

This EGFR-MOB1-YAP/TAZ signal axis may represent a new cancer treatment target

Drugs targeting YAP/TAZ have not been approved for the treatment of cancer patients

DOI

10.

Article title

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1